Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
The Liberal Democratic Party’s (LDP) tax panel on December 11 effectively signed off on creating a new “strategic technology-type” R&D tax credit with a deduction rate of 40% as part of the FY2026 tax reform package, answering a request from…
To read the full story
Related Article
- Japan’s FY2026 R&D Tax Credit Reform Wins Broad Industry Backing
April 1, 2026
- Cabinet OKs FY2026 Tax Reform Package, Creates Strategic Tech R&D Credit
January 5, 2026
- LDP, Ishin Finalize FY2026 Tax Reform Outline, Strategic Tech R&D Credit Codified
December 22, 2025
- R&D Tax Credit Draws Broad Calls for Maintenance, Expansion: LDP Meeting
December 8, 2025
- LDP Tax Panel Puts R&D Tax Credit on Political-Judgment Track for Further Talks
December 3, 2025
- As Skepticism Emerges, LDP Health Policy Chief Seeks Stronger R&D Tax Credits
November 28, 2025
- MHLW Seeks New R&D Tax Credit Scheme for Strategic Technologies in FY2026 Proposal
August 27, 2025
- Japan Mulls Preferential R&D Tax Credits for Strategic Technologies in FY2026 Reform Talks
August 22, 2025
- Ruling Parties OK FY2023 Tax Reform Outline; No More Special COVID Measure for R&D Credits
December 19, 2022
REGULATORY
- Japan, US Launch Talks on Pharma GMP MRA to Ease Inspection Burden
July 3, 2026
- MHLW Gives Kissei until July 21 to Report on Tavneos
July 3, 2026
- Centrist Reform Alliance Warns US MFN Policy Poses “Real Crisis” for Drug Access
July 3, 2026
- Ishin Urges Govt to Make Healthcare, Drug Innovation Core Growth Strategy
July 3, 2026
- MHLW Seeks Sponsors for 6 High-Need Unapproved, Off-Label Drugs
July 2, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…